Successful port-a-cath salvage using linezolid in children with acute leukemia

Area of Science:

• Pediatric Hematology
• Infectious Diseases
• Pharmacology

Background:

• Catheter-related bloodstream infections (CRBSI) are a serious complication in pediatric leukemia patients requiring central venous catheters (CVCs).
• Persistent CRBSI often necessitates CVC removal, leading to treatment interruptions and increased morbidity.
• Coagulase-negative Staphylococci are common pathogens causing CRBSI in this population.

Purpose of the Study:

• To evaluate linezolid as a salvage therapy for CRBSI caused by coagulase-negative Staphylococci in pediatric acute leukemia patients.
• To determine if linezolid treatment can prevent the removal of port-type CVCs in these challenging cases.

Main Methods:

• Retrospective analysis of six pediatric patients with acute leukemia and port-type CRBSI.
• Seven treatment courses involving simultaneous systemic and lock linezolid therapy were administered after failure of vancomycin or teicoplanin.
• Clinical outcomes, including the need for CVC removal, were assessed.

Main Results:

• Linezolid salvage therapy successfully treated CRBSI in all seven instances.
• Central venous catheter removal was avoided in all patients receiving linezolid.
• Linezolid was effective even when previous therapies (vancomycin, teicoplanin) failed.

Conclusions:

• Linezolid serves as an effective alternative salvage treatment for CRBSI in pediatric acute leukemia patients, potentially avoiding CVC removal.
• Further prospective studies are warranted to confirm the efficacy and role of linezolid in managing refractory CRBSI.